Indicaton
Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
Fosmanogepix is a novel-class i.v. and oral antifungal with activity against yeasts and molds.
Invasive aspergillosis and mucormycosis